ProPhase Labs receives Nasdaq delisting notice for bid-price non-compliance; trading to suspend Jan 5

ProPhase Labs, Inc.

Nasdaq staff determination on Dec 29, 2025: company failed to regain compliance with minimum $1.00 bid price rule after two 180-day periods ending Dec 22.
Common stock trading will be suspended at the open on Jan 5, 2026; Nasdaq will file Form 25 to remove the listing.
Company intends to timely request a hearing before Nasdaq Hearings Panel to appeal the staff determination.
Concurrently, ProPhase is applying for quotation of its common stock on the OTC Markets.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.